Dermagraft human engineered skin: The FDA granted ATIS permission to enroll about 15 additional patients

Pilot trial results showed a statistically significant improvement in complete healing, the primary end point. In addition, there was no recurrence of ulcers over an average period of 14 months versus reports in the literature of recurrence rates of 20-50 percent within 12 months. The additional patients also will provide more data on this secondary end point. ...